Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$2.95 - $3.85 $29,901 - $39,023
-10,136 Reduced 48.66%
10,693 $31,000
Q1 2023

May 15, 2023

BUY
$3.08 - $7.39 $26,180 - $62,815
8,500 Added 68.94%
20,829 $72,000
Q4 2022

Feb 14, 2023

SELL
$3.22 - $4.86 $198,123 - $299,030
-61,529 Reduced 83.31%
12,329 $51,000
Q3 2022

Nov 14, 2022

SELL
$4.01 - $12.34 $12,439 - $38,278
-3,102 Reduced 4.03%
73,858 $287,000
Q2 2022

Aug 15, 2022

BUY
$8.27 - $18.43 $399,920 - $891,237
48,358 Added 169.07%
76,960 $867,000
Q1 2022

May 16, 2022

BUY
$12.54 - $46.93 $82,864 - $310,113
6,608 Added 30.04%
28,602 $464,000
Q4 2021

Feb 14, 2022

SELL
$45.28 - $74.5 $48,540 - $79,864
-1,072 Reduced 4.65%
21,994 $1.04 Million
Q3 2021

Nov 12, 2021

SELL
$57.18 - $84.43 $142,263 - $210,061
-2,488 Reduced 9.74%
23,066 $1.67 Million
Q2 2021

Aug 13, 2021

SELL
$47.86 - $83.95 $1.09 Million - $1.91 Million
-22,793 Reduced 47.14%
25,554 $2.15 Million
Q1 2021

May 14, 2021

SELL
$44.38 - $63.97 $186,529 - $268,865
-4,203 Reduced 8.0%
48,347 $2.34 Million
Q4 2020

Feb 08, 2021

BUY
$32.94 - $47.15 $1.45 Million - $2.08 Million
44,059 Added 518.89%
52,550 $2.48 Million
Q3 2020

Nov 12, 2020

SELL
$27.46 - $47.03 $192,906 - $330,385
-7,025 Reduced 45.28%
8,491 $399,000
Q2 2020

Jul 17, 2020

SELL
$13.0 - $31.0 $55,978 - $133,486
-4,306 Reduced 21.72%
15,516 $464,000
Q1 2020

May 12, 2020

BUY
$10.63 - $15.37 $210,707 - $304,664
19,822 New
19,822 $258,000

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $77.3M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Vident Investment Advisory, LLC Portfolio

Follow Vident Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Investment Advisory, LLC with notifications on news.